Our Technology
Unleash the therapeutic potential of active pharmaceutical ingredients previously limited by unfavorable toxicities, in vivo stabilities, and pharmacokinetic profiles; enhance treatment efficacies and transform the target molecule with pharmacologically distinct mechanisms of action with Tripartite Therapeutics' proprietary OmniLink® technology.
Technology
OmniLink®
Tripartite Therapeutics' OmniLink® technology can achieve stable conjugation of cytotoxic drugs, immune adjuvants and other small bio- and chemical molecules to antibodies or antibody fragments with minimal premature release of the payloads in systemic circulation, enabling drugs with exceptionally high potency that would otherwise be hampered by dose-limiting toxicities as payloads. A high ratio of conjugated molecule per antibody (i.e. drug-antibody ratio, DAR) further augments ADC's efficacy toward all classes of tumor with different expression levels of tumor antigen. The versatility of the OmniLink® technology even allows for treatment modalities with dual mechanisms of action via dual-payload conjugations. We expect the endless treatment possibilities offered by the combination of treatment modalities to culminate both first-in-class and best-in-class treatment options in our continuous flow of product pipelines.
Applications
Cytotoxic Payload Conjugates
Despite the promise of being the “magic bullet” treatment, ADCs have so far failed to deliver meaningful improvement over existing treatment options combining protein drugs and small molecule drugs. Challenges faced by current ADCs include: (1) Hydrophobic ADC molecule is rapidly eliminated by RES, resulting in not only immune toxicity but little drug arriving at the site of action; (2) Released free payload causes systemic and hepatic toxicities; (3) In fear of aggregation and toxicity, ADC designs restricted to low DAR underlie the poor clinical performance for cancer types with low target antigen expression. All such challenges are solved with OmniLink® technology.
Immune Stimulating Payload Conjugates
Cancer immune therapy seeks to harness the body's natural immune system in the fight against cancer without the side-effects of cytotoxic payloads. Modulating the immune system can be dangerous, running the risk of self-escalating cytokine storms with lethal consequences. Tripartite's OmniLink® technology is the ideal solution to realize the potential of immune-modulating payloads. Our OmniLink® linker ensures payload stability, ensuring that the immune-response is mainly limited to the tumor environment targeted by the antibody.
Dual-payload Conjugates
Carrying two different payloads with complementary mechanisms of action is an effective means for countering drug resistance and improving therapeutic outcomes through synergistic effect exerted by the different payloads. Using Tripartite's OmniLink® technology, the same linker can be broadly adapted to the different payloads while rendering simultaneous release of them. A high drug-to-antibody ratio (DAR) of 4+4 can be achieved for dual payload ADCs.